BPC-157
Also known as Body Protection Compound 157 · PL 14736 · stable gastric pentadecapeptide
Preclinical cytoprotective peptide studied for tissue repair and GI protection in animal models.
FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
WADA S0
This substance is explicitly listed under WADA S0 (Non-Approved Substances). If you are subject to anti-doping rules, use of this substance is prohibited at all times.
Not Approved
This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.
Evidence visual
BPC-157 evidence and risk matrix
intermediate researcher fit
Evidence
Tier C
Risk
med high
Regulatory
not approved
WADA
S0
FDA
flagged
Route
subcutaneous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
BPC-157 is a 15-amino-acid peptide derived from a protein found in human gastric juice. Preclinical literature describes cytoprotective, angiogenic, and NO-system modulation signals, but the mechanism is not settled and is largely inferred from animal models. FDA has warned that compounded drugs containing BPC-157 may pose risks including immunogenicity concerns and insufficient safety information for proposed routes. WADA explicitly lists BPC-157 under S0 non-approved substances.
Decision path
Where BPC-157 fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether BPC-157 belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Preclinical cytoprotective and angiogenic signaling via NO-system modulation; mechanism not settled, largely inferred from animal models.
subcutaneous, oral
Rodent: ~10 µg/kg systemic; oral exposure at µg/kg levels. No established human dosing.
Preclinical: angiogenesis markers, tissue repair signals, GI mucosal protection in rodent models.
Animal models: endpoints assessed over days to weeks (2-4 weeks in injury models).
No established human contraindications (insufficient data).
Insufficient human data; immunogenicity risk flagged by FDA; impurity characterization concerns.
No robust human interaction map; avoid confident stacking claims.
Cost at a glance
Typical cycle cost
$118.99
Estimated monthly
$79.32
Protocol style
4-6 week burst
Short burst
Estimate confidence
High confidence
Assumes roughly 8 mg–14 mg per cycle, using 2 tracked affiliated listings.
Modeled as a short repair-focused run rather than an indefinite therapy.
Age, sex, and monitoring
Life-stage fit
Commonly researched by active adults for recovery, but still lacks validated human age-specific evidence.
Best fit age ranges: 25-34, 35-44, 45-54
65+
Very limited human evidence makes this a weak fit for older-adult decision-making.
Known Interactions
Commonly marketed as a stack/blend in consumer market; clinical interaction evidence limited; treat as uncertain.
Commonly co-marketed; limited interaction evidence; treat as uncertain.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for BPC-157.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.